Xiang, Yang; Ma, Long; Wu, Weidong; Liu, Wei; Li, Yongguang; Zhu, Xia; Wang, Qian; Ma, Jinfeng; Cao, Mingqin; Wang, Qian; +8 more... Yao, Xuemei; Yang, Lei; Wubuli, Atikaimu; Merle, Corinne; Milligan, Paul; Mao, Ying; Gu, Jiayi; Xin, Xiumei; (2014) The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PloS one, 9 (1). e85905-. ISSN 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0085905

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/1496164/

DOI: https://doi.org/10.1371/journal.pone.0085905

Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
The Incidence of Liver Injury in Uyghur Patients Treated for TB in Xinjiang Uyghur Autonomous Region, China, and Its Association with Hepatic Enzyme Polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1

Yang Xiang1, Long Ma2*, Weidong Wu3, Wei Liu4, Yongguang Li5, Xia Zhu6, Qian Wang7, Jinfeng Ma1, Mingqin Cao1, Qian Wang1, Xuemei Yao1, Lei Yang1, Atikaimu Wubuli1, Corinne Merle8, Paul Milligan8, Ying Mao1, Jiayi Gu1, Xiumei Xin9

1 Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China, 2 The Red Cross of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China, 3 Center for Tuberculosis Control and Prevention, Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, Xinjiang, China, 4 Xinjiang Ill Kazak Autonomous Prefecture Centers for Disease Control and Prevention, Ili, Xinjiang, China, 5 Xinjiang Aksu District Center for Disease Control and Prevention, Aksu, Xinjiang, China, 6 Library of Xinjiang Medical University, Urumqi, Xinjiang, China, 7 Graduation School of Xinjiang Medical University, Urumqi, Xinjiang, China, 8 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom, 9 Care Division, the Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China

Abstract

Background and Objective: Of three first-line anti-tuberculosis (anti-TB) drugs, isoniazid is most commonly associated with hepatotoxicity. Differences in INH-induced toxicity have been attributed to genetic variability at several loci, NAT2, CYP2E1, GSTM1 and GSTT1, that code for drug-metabolizing enzymes. This study evaluated whether the polymorphisms in these enzymes were associated with an increased risk of anti-TB drug-induced hepatitis in patients and could potentially be used to identify patients at risk of liver injury.

Methods and Design: In a cross-sectional study, 2244 tuberculosis patients were assessed two months after the start of treatment. Anti-TB drug-induced liver injury (ATLI) was defined as an ALT, AST or bilirubin value more than twice the upper limit of normal. NAT2, CYP2E1, GSTM1 and GSTT1 genotypes were determined using the PCR/ligase detection reaction assays.

Results: 2244 patients were evaluated, there were 89 cases of ATLI, a prevalence of 4% 9 patients (0.4%) had ALT levels more than 5 times the upper limit of normal. The prevalence of ATLI was greater among men than women, and there was a weak association with NAT2*5 genotypes, with ATLI more common among patients with the NAT2*5*CT genotype. The sensitivity of the CT genotype for identifying patients with ATLI was 42% and the positive predictive value 5.9%. CT ATLI was more common among slow acetylators (prevalence ratio 2.0 (95% CI 0.95, 4.20) compared to rapid acetylators. There was no evidence that ATLI was associated with CYP2E1 RsaI c1/c1 genotypes, CYP2E1 RsaI c1/c2 or c2/c2 genotypes, or GSTM1/GSTT1 null genotypes.

Conclusions: In Xinjiang Uyghur TB patients, liver injury was associated with the genetic variant NAT2*5, however the genetic markers studied are unlikely to be useful for screening patients due to the low sensitivity and low positive predictive values for identifying persons at risk of liver injury.

Introduction

China has a high incidence of tuberculosis (TB), ranking second in the world in terms of number of cases [1]. In Xinjiang, Northwestern China, the incidence of TB, the prevalence of smear positive TB and the TB mortality rate are higher than the national average and the Uyghur population are particularly at risk, but the prevalence of drug-induced liver injury, and associated risk factors, in this population have not been previously reported. The Directly Observed Treatment Short-course (DOTS), recommended by World Health Organization (WHO), constitutes the cornerstone of the current strategy for control of tuberculosis and covers the entire population of China. A combination of the three drugs, isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) is used...
as the first-line therapy. However, multi-drug combination therapy is known to increase the risk of severe adverse drug reactions (ADRs) such as hepatotoxicity, gastrointestinal disorders, allergic reactions, arthralgia, neurological disorders, and other symptoms [2,3]. Anti-TB drug-induced liver injury (ATLI) is the most prevalent and serious ADR encountered in the course of TB treatment [4]. In addition to the direct harm of ATLI, toxicity leads to early withdrawal from treatment, compromising the effectiveness of TB control (the China National Tuberculosis Prevention and Control Scheme (CNTS)) [5]. The pathogenic mechanism of ATLI is still obscure [6]; a better understanding of the pathogenic mechanism may help to guide individual treatment and the implementation of the national anti-tuberculosis treatment program.

Anti-tuberculosis drug-induced hepatotoxicity is caused by the production of toxic metabolites of treatment drugs, associated with the presence of certain genetic variants of liver enzymes. These polymorphisms could potentially be used for screening patients and guiding their therapy. Among the first line anti-tuberculosis drugs, INH is more commonly associated with ATLI [7,8], especially when used in combination with PZA. INH is metabolized to acetylisoniazid via hepatic N-acetyltransferase 2 (NAT-2) [8]. In turn, acetylsalicylic acid is hydrolysed to acetylsalicylic acid, which is primarily oxidized by cytochrome P4502E1 to some hepatic intermediates [8,9]. Direct hydrolysis of INH also generates hydrazine, a potent hepatotoxin. The hepatotoxins generated by NAT2 or CYP2E1 may be further detoxified by glutathione S-transferases (GSTs) (such as GSTM1 and GSTT1) present in the liver [10]. Disposal of acetylhydrazine also depends on further acetylation by NAT2 to form a non-toxic metabolite, diacetylhydrazine [8]. Therefore, studies on genetic predisposition for ATLI have focused on a few metabolizing enzymes including NAT2, CYP2E1, GSTM1 and GSTT1. These enzymes are polymorphic, and the distribution of these polymorphisms varies among ethnic groups. Persons deficient in hepatic N-acetyltransferase may accumulate drugs that require acetylation. Individuals may be rapid, intermediate or slow acetylators, according to their activity of NAT2 [11], however the link between acetylator status and risk of ATLI has been inconsistent in previous studies [8,12-22]. Inconsistent results have also been reported for the CYP2E1 polymorphisms [17,18,23-30]. Persons homozygous for GSTM1 or the GSTT1null (non-functional) genotype, which cause lack of enzyme activity, have been found to be at increased risk of ATLI in some studies but again the results have been conflicting [17,29,31–38].

We assessed Uygur patients treated for TB in Xinjiang receiving short-course chemotherapeutic treatment recommended by WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, prior to the 2-month visit, were invited to participate. Signed consent was sought after explaining the aims and procedures of the study. Patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels), or disease associated with liver dysfunction, were excluded. The study protocol was approved by the Ethics Committee of First Affiliated Hospital of Xinjiang Medical University.

All patients were prescribed INH (600 mg), RMP (600 mg, or 450 mg if the body weight was less than 50 kg), PZA (2,000 mg), and ethambutol (EMB) (1,250 mg) every other day in the first two months. After the two-month, INH and RMP were continued for a further four to six months. Retreatment patients in addition received streptomycin (SM) (750 mg) every other day in the first two months and continued receiving EMB for another six months. When patients developed a suspected Adverse Drug Reaction (ADR) (ATLI, gastrointestinal reaction, allergic reaction, nervous system disorders, or arthralgia), their treatment was adjusted according to the severity of the symptoms.

At the end of two months of anti-tuberculosis treatment, or if patients presented with symptoms suggestive of hepatitis (such as anorexia, nausea, vomiting, malaise) prior to the two-month visit, serum ALT, AST and total bilirubin levels were measured and a sample of each patient’s blood was stored for genotypic analysis. Patients were interviewed using a structured questionnaire and demographic information (gender, age, ethnicity), weight and height, TB treatment history, anti-tuberculosis treatment induced ADRs, clinical symptoms, and risk factors for liver disease, was recorded. Case notes of all suspected cases of ATLI were then reviewed and assessed by a clinician.

**Definition of ATLI**

In the primary analysis ATLI was defined as an ALT, AST or bilirubin value more than two times the upper limit of normal value [39]. The upper limit of normal used in the study was 40 U/L for ALT, 40 U/L for AST, and 19 μmol/L for total bilirubin. In secondary analyses we considered alternative case definitions, firstly with ATLI defined as values above three or above 5 times the upper limit of normal, and secondly defined as ATLI if patient ALT, AST or bilirubin levels corresponded to grade 3 or grade 4 adverse events in the The Division of AIDS table for grading the severity of adult and pediatric adverse events [http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Averse_Events.pdf].

**DNA Preparation and Genotyping**

Genomic DNA was extracted from peripheral blood leukocytes using the DNA isolation kit RelaxGene blood DNA DP319-02 (Tiangen, China) following the manufacturer’s instructions and was stored at −20°C until used for genotyping, which was carried out by Shanghai BioWing Applied Biotechnology Company (http://www.biowing.com.cn).

In this study, we chose three NAT2 SNPs (SNP1 rs1799929, SNP2 rs1799930 and SNP3 rs1799931) which have been shown to be associated with ATLI in adults treated with anti-tuberculosis drugs. All three SNPs of NAT2 were genotyped using the PCR/ligase detection reaction assay. The primers were 5'- CCT CTC CTG CAG GTG ACC AT-3’ and 5'- AGC ATG AAT CAC TGT CTT GC TT-3’. Each set of ligase detection reaction probes comprised one common probe and two discriminating probes for the two types.
The target DNA sequences were amplified using a multiplex PCR method. PCR was performed in a final volume of 20 μl containing 1× PCR buffer, 3.0 mmol/l MgCl₂, 2.0 mmol/l deoxynucleotide triphosphates, 0.4 μl primers, 0.3 μl Qiagen HotStarTaq Polymerase (QIAGEN, China), 4 μl of 1×Q-solution, and 50 ng genomic DNA. Thermal cycling was performed in Gene Amp PCR system 9600 (PerkinElmer) with an initial denaturation of at 95°C for 15 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 62°C for 90 s, and extension at 64°C for 90 s, followed by a final extension at 64°C for 10 min.

The ligation reaction for each subject was carried out in a final volume of 10 μl containing 1× NEB Taq DNA ligase buffer, 12.5 pmol of each probe mix, 0.05 μl Taq DNA ligase (NEB Biotechnology (Beijing)), and 1 μl of multi-PCR product. A total of 35 cycles for ligase detection reaction was performed using 35 cycles at 95°C for 2 min, 94°C for 30 s, and 50°C for 2 min. The fluorescent products of ligase detection reaction were differentiated by ABI sequencer 377 (ABI).

Individuals were classified into three groups as follows: rapid acetylators (RA: a homozygote of NAT2*4), an intermediate acetylator genotype (IA: a heterozygote of NAT2*4 and mutant alleles) and a slow acetylator genotype (SA: a combination of mutant alleles), as in the Table 1.

For the Rsal SNP rs2031920 genotyping of CYP2E1, the method was the same as described above for NAT2. The primers were 5′-TTCATTCTGTCTTCTAACTGG-3′ and 5′-CCAGTCGAGTCGACATTGTCA-3′.

### Statistical Methods

The primary analysis employed a definition of ATLI as ALT, AST or bilirubin more than twice the upper limit of normal, in a secondary analysis, ATLI was defined using a threshold of three times the upper limit of normal. Association analyses were done after excluding 297 individuals who had elevated levels of ALT, AST or bilirubin but did not meet the criteria for ATLI that could not be confidently ascribed as cases or non-cases, and individuals with missing genotype data. Association of ATLI with genotypes

| Table 1. Definition of acetylator status according to NAT2 genotypes. |
|-------------------------------|-------------------|-------------------|-------------------|
| **NAT2*5** (rs1799929) | **NAT2*6** (rs1799930) | **NAT2*7** (rs1799931) | **Acetylator genotypes** | **Acetylator status** |
| C C | G G | G G | NAT2*4/4 | RA |
| C T | G G | G G | NAT2*4/5 | IA |
| C C | A G | G G | NAT2*4/6 | IA |
| C C | G G | A G | NAT2*4/7 | IA |
| T T | G G | G G | NAT2*5/5 | SA |
| C T | A G | G G | NAT2*5/6 | SA |
| C T | G G | A G | NAT2*5/7 | SA |
| C C | A A | G G | NAT2*6/6 | SA |
| C C | A G | A G | NAT2*6/7 | SA |
| C C | G G | A A | NAT2*7/7 | SA |

doi:10.1371/journal.pone.0085905.t001

| Table 2. Characteristics of patients. |
|-----------------------------|-----------------------------|-----------------------------|
| **Patients with ATLI** | **Patients with elevated ALT, AST, or bilirubin** | **Patients with normal ALT, AST, bilirubin** |
| Mean age in years (range) | 37 (24–56) | 43 (26–60) | 46 (27–61) |
| BMI (kg/m2) | 20.3 (18.4–22.6) | 21.0 (19.3–22.7) | 21.4 (19.5–22.9) |
| INH (mg/kg/day) | 4.8 (4.6–5.4) | 5.2 (4.7–5.8) | 5.4 (4.7–6.0) |
| PZA (mg/kg/day) | 16.1 (15.2–17.9) | 17.2 (15.6–19.2) | 17.9 (15.6–20.0) |
| Liver function tests at 2 months: | | | |
| ALT | 110.0 (84.3–147.0) | 45.6 (37.5–54.8) | 22.2 (16.8–29.0) |
| AST | 91.4 (66.2–114.0) | 42.5 (35.3–51.0) | 23.0 (17.0–30.0) |
| bilirubin (μmol/L) | 9.7 (5.1–16.5) | 11.0 (6.7–14.0) | 9.7 (6.0–12.5) |

doi:10.1371/journal.pone.0085905.t002
was assessed with the Cochrane-Armitage test and for acetylator status was assessed using a test for trend. 95% confidence intervals for the prevalence ratio were calculated using standard methods. All statistical analyses were conducted using SPSS software version 17.0 (SPSS, Chicago, IL) or Stata version 12 (College Station, Texas). The chi-square test was used to test for Hardy–Weinberg equilibrium.

Results

Characteristics of Patients and Incidence of ATLI

A total of 2244 Uyghur patients who had completed 2-months follow-up were assessed. 1858 (83%) had normal levels of AST, ALT and bilirubin; 297 (13%) had elevated levels but did not meet the criteria for ATLI, and 89 patients (4%) were diagnosed with ATLI. Among these 89 cases, 74 had an ALT level above two times the upper limit of normal, and 15 patients had AST or total bilirubin above twice the upper limit of normal. 58/89 patients ALT, AST or bilirubin had two to three times of ULN (47 in ALT and 11 in AST/total bilirubin), 22/89 patients had levels three to five times of ULN (18 in ALT and 4 in AST/total bilirubin) and 9/89 had more than five times of ULN (all in ALT). Fifty-nine of the ATLI patients reported clinical symptoms (nausea, vomiting, anorexia or malaise). The baseline characteristics, dosages and liver function test results of the patient are shown in Table 2. The overall prevalence of ATLI was 4%, with increased risk among males, and in the south of Xinjiang compared to the north (Table 3).

NAT2 Polymorphism in Patients with and without ATLI

Genotype distributions of NAT2, CYP2E1 and GSTM1 and GSTT1 variants, among individuals who had normal levels for liver function tests, agreed with the Hardy-Weinberg equilibrium. NAT2*5, NAT2*6 and NAT2*7 were successfully genotyped in 1458, 1451 and 1468 subjects respectively. The NAT2*5 genotypes were associated with ATLI, with an increased prevalence in persons with the CT genotype, compared to CC, with a prevalence ratio of 1.70, 95% CI 1.10–2.70, Table 4. The sensitivity of the CT genotype for predicting ATLI was 42% and the positive predictive value 5.9%. There was no evidence of an association of NAT2*6 or NAT2*7 genotypes with ATLI. There was weak evidence of an association between ATLI and NAT2 acetylator status, (P-value for trend 0.06), with a 2-fold increase in prevalence in the slow acetylator group compared to rapid acetylators (prevalence ratio 2.0 (95% CI 0.95,4.20), Table 5).

Among the slow-acetylator genotypes, the NAT2?5/6 genotypes was most strongly associated with ATLI (Table 6), sensitivity 25% and positive predictive value 7.5%.

CYP2E1 and GSTs Polymorphism in Patients with and without ATLI

The C1/C1 genotype of the CYP2E1 gene was most common in both the study groups. Only 1.9% of non-ATLI patients were found to carry the C2/C2 genotype of the CYP2E1 gene, and no ATLI case was found with the C2/C2 genotype (Table 7). There was no evidence of an association of the CYP2E1 Rsa?polymorphism, or the single or combined null GSTs genotypes, with ATLI.

Discussion

Xinjiang ranks second highest in terms of the prevalence of TB and fifth highest prevalence of HIV of provinces in China. Xinjiang is an ethnically diverse region with Uyghur people forming 46% of the population. This is the first study to investigate the incidence of and risk factors for hepatic injury in TB patients in the Uyghur population. A better understanding of the risk factors and mechanisms of drug-induced hepatotoxicity may help to prevention this iatrogenic hepatic injury, which can be fatal. The study in over 2000 patients found a high incidence of elevated liver enzymes with 4% of patients with signs of liver injury after two months of treatment. Incidence was higher among men than women, and was higher among younger patients (under 40yrs)
than in older groups. The association with gender is different from that seen in other studies, we did not find any gender-related predisposing factors which might explain the gender difference. Some studies [27,40,41] have shown that the women are at an increased risk of developing drug-induced hepatotoxicity during treatment of TB, but most studies did not find an association with gender [17,18,23,25,26,28,29,32,34,36,42,43].

Acetylator status was associated with drug-induced hepatotoxicity, as has been reported in a number of previous studies [16,18,20–22,24–26,28,44–47]. The genetic variant of NAT2*5 was associated with ATLI, in contrast to results from two recent case-control studies in TB patients in the Chinese Han population [19,31] which did not find an association of four common SNPs with ATLI. However the association was weak and the sensitivity of the markers studied for identifying persons with ATLI was low.

### Table 4. Prevalence of ATLI according to N-acetyltransferase 2 (NAT2) genotype.

| Genotype       | Patients With ATLI | Patients with elevated ALT, AST, or bilirubin | Patients with normal ALT, AST and bilirubin levels | Total | Prevalence of ATLI % | Prevalence ratio (95% CI) | P-value[^d] |
|----------------|--------------------|-----------------------------------------------|---------------------------------------------------|-------|---------------------|--------------------------|-------------|
| NAT2*5 (rs1799929) |                    |                                               |                                                   |       |                     |                          |             |
| CC             | 39                 | 158                                           | 928                                               | 1125  | 3.50%               | 1                        | 0.0623      |
| CT             | 30                 | 81                                            | 397                                               | 508   | 5.90%               | 1.7                      |             |
| TT             | 2                  | 7                                             | 62                                                | 69    | 2.80%               | 0.81                     |             |
| Allelefrequency|                    |                                               |                                                   |       |                     |                          |             |
| C              | 76.10%             |                                               | 81.20%                                           |       |                     |                          |             |
| T              | 23.90%             |                                               | 18.80%                                           |       |                     |                          |             |
| NAT2*6 (rs1799930) |                    |                                               |                                                   |       |                     |                          |             |
| GG             | 35                 | 124                                           | 801                                               | 960   | 3.60%               | 1                        | 0.4016      |
| GA             | 30                 | 98                                            | 465                                               | 593   | 5.10%               | 1.4                      |             |
| AA             | 6                  | 21                                            | 114                                               | 141   | 4.30%               | 1.2                      |             |
| Allelefrequency|                    |                                               |                                                   |       |                     |                          |             |
| G              | 70.40%             |                                               | 74.90%                                           |       |                     |                          |             |
| T              | 29.60%             |                                               | 25.10%                                           |       |                     |                          |             |
| NAT2*7 (rs1799931) |                    |                                               |                                                   |       |                     |                          |             |
| GG             | 58                 | 198                                           | 1103                                              | 1359  | 4.30%               | 1                        | 0.8623      |
| GA             | 12                 | 45                                            | 274                                               | 331   | 3.60%               | 0.85                     |             |
| AA             | 1                  | 0                                             | 20                                                | 21    | 4.80%               | 1.1                      |             |
| Allelefrequency|                    |                                               |                                                   |       |                     |                          |             |
| G              | 90.10%             |                                               | 88.80%                                           |       |                     |                          |             |
| A              | 9.90%              |                                               | 11.20%                                           |       |                     |                          |             |
| not typed      | 18                 |                                               | 461                                               | 479   | 3.80%               |                          |             |
| TOTAL          | 89                 | 297                                           | 1858                                              | 2244  | 4.00%               |                          |             |

[^d]: Cochrane-Armitage test.
doi:10.1371/journal.pone.0085905.t004

### Table 5. Prevalence of ATLI in patients according to acetylator status.

| Acetylator status: | Patients With ATLI | Patients with elevated ALT, AST, or bilirubin | Patients with normal ALT, AST and bilirubin levels | Total | Prevalence of ATLI % | Prevalence ratio (95% CI) | P-value[^d] |
|--------------------|--------------------|-----------------------------------------------|---------------------------------------------------|-------|---------------------|--------------------------|-------------|
| Rapid (RA)         | 9                  | 41                                            | 287                                               | 337   | 2.70%               | 1                        | 0.0616      |
| Intermediate (IA)  | 34                 | 118                                           | 667                                               | 819   | 4.20%               | 1.60 (0.75,3.20)          |             |
| Slow (SA)          | 28                 | 79                                            | 422                                               | 529   | 5.30%               | 2.00 (0.95,4.20)          |             |
| not typed          | 18                 | 59                                            | 482                                               | 559   | 3.20%               |                          |             |
| TOTAL              | 89                 | 297                                           | 1858                                              | 2244  | 4.00%               |                          |             |

[^d]: Cochrane-Armitage test for trend.
doi:10.1371/journal.pone.0085905.t005
We employed the same case definition for ATLI used in a number of previous studies. When more restrictive definitions were used, the number of cases was reduced but the predictive value of the genetic markers remained low.

A limitation of the present study is that although before starting anti-tuberculosis therapy, it is normal practice for liver and renal function to be tested, it was not possible to confirm that these tests were performed. It is therefore the possibility that some patients had signs of liver disease that were missed when treatment started cannot be ruled out. We did not have detailed information about adherence, and there may be residual confounding due to uncontrolled risk factors for liver disease, although alcohol consumption is unlikely to be an important factor in this Muslim population. In addition, other plausible candidate genes associated with the ATLI need to be explored [48].

The disposition of anti-tuberculosis drug is related to the activity of many drug-metabolizing enzymes (DMEs), including NAT2, CYP2E1, and GST. Polymorphisms of some encoding genes may influence the activity of the corresponding DMEs. In view of NAT2*5(C481T, rs1799929), NAT2*6 (G590A, rs1799930), and NAT2*7(G857A, rs1799931) mutations accounted for virtually all of the slow acetylator alleles in Asians, we have evaluated the roles of NAT2*5, NAT2*6, and NAT2*7 in the developing of ATLI basing on our community-based TB patients.

### Table 6. Prevalence of ATLI by NAT genotype.

| Acetylator status | Genotype  | Patients With ATLI | Patients with elevated ALT, AST, or bilirubin | Patients with normal ALT, AST and bilirubin levels | Total | Prevalence of ATLI % | Prevalence ratio (95% CI) |
|------------------|-----------|--------------------|---------------------------------|---------------------------------|------|---------------------|------------------------|
| Rapid            | NAT2*4/4  | 9                  | 41                              | 287                             | 337  | 2.7%                | 1.00                   |
| Intermediate     | NAT2*4/5  | 12                 | 41                              | 231                             | 284  | 4.2%                | 1.58 (0.68, 3.70)      |
|                  | NAT2*4/6  | 16                 | 54                              | 285                             | 355  | 4.5%                | 1.69 (0.76, 3.80)      |
|                  | NAT2*4/7  | 6                  | 23                              | 151                             | 180  | 3.3%                | 1.25 (0.48, 3.30)      |
| Slow             | NAT2*5/5  | 2                  | 7                               | 62                              | 71   | 2.8%                | 1.05 (0.25, 4.50)      |
|                  | NAT2*5/6  | 13                 | 31                              | 113                             | 157  | 8.3%                | 3.10 (1.20, 8.00)      |
|                  | NAT2*5/7  | 5                  | 8                               | 51                              | 64   | 7.8%                | 2.93 (0.59, 15.00)     |
|                  | NAT2*6/6  | 6                  | 20                              | 111                             | 137  | 4.4%                | 1.64 (0.64, 4.20)      |
|                  | NAT2*6/7  | 1                  | 13                              | 67                              | 81   | 1.2%                | 0.46 (0.06, 3.90)      |
|                  | NAT2*7/7  | 1                  | 0                               | 18                              | 19   | 5.3%                | 1.97 (0.25, 15.00)     |
| not typed        |           | 18                 | 59                              | 482                             | 559  | 3.2%                |                        |
| TOTAL            |           | 89                 | 297                             | 1858                            | 2244 | 4.0%                |                        |

**Table 7. Genetic polymorphisms of CYP2E1, GSTM1 and GSTT1 and the prevalence of ATLI.**

| Variant          | Patients With ATLI | Patients with elevated ALT, AST, or bilirubin | Patients with normal ALT, AST and bilirubin levels | Prevalence of ATLI % | Prevalence ratio (95% CI) | P-value* |
|------------------|--------------------|---------------------------------|---------------------------------|---------------------|------------------------|----------|
| CYP2E1 Rsa I     | C1/C1              | 58                              | 198                             | 1066                | 4.40%                  | 1        | 0.4708               |
| (rs2031920):     | C1/C2              | 12                              | 41                              | 267                 | 3.80%                  | 0.85 (0.46, 1.57)     |
|                  | C2/C2              | 0                               | 2                               | 26                  | 0.00%                  | 0        |                      |
|                  | not typed          | 19                              | 56                              | 499                 |                        |          |                      |
| Allele frequency | C1                 | 91.40%                          |                                  |                     |                        |          |                      |
|                  | C2                 | 8.60%                           |                                  |                     |                        |          |                      |
| GSTM:            | GSTM1*1            | 34                              | 116                             | 669                 | 4.20%                  | 1        | 0.527                |
|                  | GSTM1null          | 41                              | 133                             | 792                 | 4.20%                  | 1.02 (0.66, 1.60)     |
|                  | not typed          | 14                              | 48                              | 397                 |                        |          |                      |
| GSTT:            | GSTT1*1            | 57                              | 193                             | 1041                | 4.40%                  | 1        | 0.4627               |
|                  | GSTT1null          | 18                              | 57                              | 420                 | 3.60%                  | 0.82 (0.49, 1.40)     |
|                  | not typed          | 14                              | 47                              | 397                 |                        |          |                      |
| GSTM1/GSTT1:     | M1*1/T1*1          | 23                              | 89                              | 502                 | 3.70%                  | 1        | 0.2289               |
|                  | M1*1/T1null        | 11                              | 27                              | 167                 | 5.40%                  | 1.40 (0.71, 2.90)     |
|                  | M1null/T1*1        | 34                              | 103                             | 539                 | 5.00%                  | 1.30 (0.69, 2.60)     |
|                  | M1null/T1null      | 7                               | 30                              | 253                 | 2.40%                  | 0.64 (0.29, 1.40)     |

*Cochrane-Armitage test.

doi:10.1371/journal.pone.0085905.t006
did not find NAT2*6 and NAT2*7 were risk for developing ATLI, while other studies [18,44,45,49] have reported NAT2*6 and NAT2*7 had a higher incidence of drug-induced hepatotoxicity. However, the association of NAT2*5 and ATLI observed in our study population, agrees with findings of Possuelo LG et al., in southern Brazil [44].

Acetylation activity in vitro is ranked in the sequence: NAT2*>NAT2*7>NAT2*6/>NAT2*5 [16,46]. The NAT2*5 mutant homogeneous genotype has not been reported in some previous studies [19,47,49], but in Uygur patients NAT2*5 is the predominant allele with low acetylation activity. Slow acetylators homozygous for the NAT2*5 allele may acetylate isoniazid more slowly. This is in line with our finding that slow acetylators with NAT2*5/6 has a significantly higher risk of anti-tuberculosis drug-induced hepatitis than other genotypes.

These results may reflect ethnic differences. The proportion of rapid, intermediate and slow acetylators in this study (21%, 49% and 31% respectively) differs from that reported for the healthy Chinese population [50] (30%,45% and 25%) and from other results [19]. This may be due to the presence of other polymorphisms in the NAT2 gene. Studying other polymorphisms, such as NAT2*12 and NAT2*13, may help to clarify these conflicting results.

Among several CYP2E1 genetic polymorphisms, the Rsal polymorphism has been evaluated mostly in association with ATLI, explained by a higher CYP2E1 activity with the c1/c1 genotype and the inhibitory effect of INH [17,26,29,45,51]. Some studies have found the relationship between the CYP2E1 Rsal c1/c1 genotype and the risk of anti-TB drug-induced hepatitis [17,23,26,43,31,32].

Huang et al. [23] in a Taiwanese population demonstrated that the CYP2E1 c1/c1 genotype increased the risk of anti-TB drug-induced hepatotoxicity, and similar results have been found in China [17]. Other studies found conflicting results [18,24,25,27–31,53]. Two recent studies in China showed no evidence of association between CYP2E1 c1/c1 genotype and ATLI [24,31]. In our study, the CYP2E1 mutant genotype was rare and therefore unlikely to be useful as a predictor of ATLI risk.

GST, which plays an important protective role in preventing ATLI, exists in several isoforms. [10,54] Some genetic loci, notably GSTM1 and GSTT1, are polymorphic. Homozygous 'null' mutations result in a complete absence of enzyme activity. It is speculated that people with null GSTM1 or GSTT1 genotypes could not detoxify the toxic reactive metabolites efficiently, and thus have higher risk of ATLI. Some studies have reported a relationship between GSTM1 null [17,29–30] and GSTT1[29–38] null genotype, and ATLI. However, most of these studies [29–34] found no evidence of an association, including studies in the Chinese population.

According to the model of the pathogenesis of drug-induced hepatotoxicity proposed by Russmann et al., the biochemical mechanism of drug-induced hepatotoxicity may involve a complex interplay between the chemical properties of the drug, environmental factors (such as age, sex, diet, alcohol consumption, compliance of drug intake, existing liver disease, concomitant use of other drugs and comorbid illness) and genetic factors that control the handling of the drug (metabolism, detoxification, and transport), as well as those that influence cell injury and repair [55]. The development of pharmacogenomics enables more extensive studies using larger sample sizes and high-throughput DNA microarrays, which may include more genotypes of relevant DMEs [15]. Most previous studies have been based on the INH metabolic pathway [56], but INH, RMP and PZA are all hepatotoxic drugs [57] and different may have different pathogenic mechanisms [58]. Other factors may influence gene expression transcription and translation of CYP2E1. Gene methylation may influence the expression of CYP [59]. Vieira et al. [60] reported an association between CYP2E1 transcripts and decreased methylation of CpG residues in intron 1 of the CYP2E1 gene, during the late neonatal period. In addition microRNA (miRNA) regulation of CYP has been described [59]. Human CYP2E1 expression is regulated by miR-378, mainly via translational repression [61]. Some studies indicate that a mutant C allele of manganese superoxide dismutase, the absence of HLA-DQA1*0102 and the presence of HLA-DQA1*0102 alleles, may be associated with ATLI [37,62]. The biochemical mechanism and pathogenesis of ATLI is complex and multifactorial, it may be valuable to combine several risk factors to identify patients at increased risk of ATLI.

Acknowledgments
We are grateful to all cooperating organizations (Center for Disease and Control Prevention in Xinjiang Uygur Autonomous Region, Ilı Kazak Autonomous Prefecture and Aksu District) and their staffs whose hard work made this study possible. Special thanks to the TB patients participating in this study.

Author Contributions
Conceived and designed the experiments: YX LM WDW. Performed the experiments: WL YGL XZ QW (Qian Wang of Graduation School of Xinjiang Medical University, Urumqi, Xinjiang, China) XMY LY YM JYG XMX. Analyzed the data: JFM MQC QW (Qian Wang of Graduation School of Xinjiang Medical University, Urumqi, Xinjiang, China) CM PM. Wrote the paper: YX AW PM.

References
1. World Health Organization (2011) Global tuberculosis control: WHO report 2011. Geneva: World Health Organization. 1–11.
2. Bumann WJ, Reeves RR (2001) Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med 164: 1112–1113.
3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, et al. (2003) Incidence of serious side-effects from first-line antituberculous drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472–1477.
4. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 953–952.
5. Devabhakti H (2011) Antituberculous drug-induced liver injury: current perspective. Top Gastroenterol 32: 167–174.
6. Yew WW, Leung CC (2006) Drug-induced hepatotoxicity. N Engl J Med 333: 1118–1127.
7. Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med 333: 1118–1127.
8. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgerisson U, Timbrell JA, et al. (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84: 101–192.
9. Runge-Morris M, Feng Y, Zangar R C, Novak R F (1996) Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos 24: 734.
10. Strange RC, Jones PW, Fryer AA (2000) Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 112–113: 357–363.
11. Sunahara S, Urano M, Ogawa M (1961) Genetical and geographic studies on isoniazid hepatitis in Japan. Proc Jpn Acad 37: 51–56.
12. Runge-Morris M, Feng Y, Zangar R C, Novak R F (1996) Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos 24: 734.
13. Strange RC, Jones PW, Fryer AA (2000) Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 112–113: 357–363.
14. Sunahara S, Urano M, Ogawa M (1961) Genetical and geographic studies on isoniazid inactivation. Science 10: 1539–1541.
15. Mitchell JR, Thorgerisson U, Black M, Timbrell JA, Snodgrass WR, et al. (1975) Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 18: 70–79.
16. Yamamoto T, Suido T, Hirayama C (1986) Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6: 295–299.
14. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51: 132-136.

15. Huang Y S (2007) Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 3: 1-8.

16. Huang YS, Chen HD, Su WJ, Wu JC, Lai SL, et al. (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35: 883-889.

17. Wang T, Yu HT, Wang W, Pan YY, He LX, et al. (2010) Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res 38: 977-980.

18. Lee SW, Chang LS, Huang HH, Chuang TY, Liu YH, et al. (2010) NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14: 622-626.

19. Li XZ, Tang SW, Xia YY, Zhang Y, Wu SS, et al. (2012) NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese population. Am Hepatol 11: 700-707.

20. Guo M, Guo YH, Li SM, Wang D, Liu Q, et al. (2010) [The relationship between polymorphisms of N-acetyltransferase 2 genes and antituberculosis drug induced hepatic injury]. Zhonghua Chuan Ran Bing Za Zhi 28: 99-102.

21. Huang DS, Zou YH, He G, LV JC, Wang YN (2011) [Association between polymorphism of N-acetyltransferase 2 gene and development of antituberculosis drug-induced liver injury]. ZhongHua Sheng Wu Yi Xue Gong Cheng Za Zhi 17: 444-447.

22. Ohino M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, et al. (2003) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4: 256-261.

23. Huang YS, Chen HD, Su WJ, Wu JC, Chang YS, Shin ES, et al. (2001) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatotoxicity. Hepatology 37: 924-930.

24. An HR, Wu UQ, Wang ZY, Zhang JX (2012) NAT 2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 39: 535-543.

25. Cho HJ, Koh WJ, Ryu VJ, Kim CS, Nam MH, et al. (2007) Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Koreans. Tuberculosis (Edinb) 90: 39-43.

26. Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, et al. (2006) Genetic variations of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 4: 256-261.

27. Huang YS, Chen HD, Su WJ, Wu JC, Lai SL, et al. (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35: 883-889.

28. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, et al. (2003) Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol 18: 1033-1037.

29. Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11: 272-276.

30. Dossing M, Wilcke JT, Asgaard DS, Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tuberculosis 167: 335-340.

31. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, et al. (2003) Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol 18: 1033-1037.

32. Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11: 272-276.

33. Dossing M, Wilcke JT, Asgaard DS, Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tuberculosis 167: 335-340.

34. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, et al. (2003) Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol 18: 1033-1037.

35. Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11: 272-276.

36. Dossing M, Wilcke JT, Asgaard DS, Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tuberculosis 167: 335-340.